BackReport summary

ZTS

Zoetis Inc.

Zoetis (ZTS) Q2 2026 earnings

Published Aug 6, 2026

AI summary

  • Revenue $2.47B, down 0.2% from $2.47B a year ago.
  • Adjusted EPS $1.87 beat the $1.85 consensus by $0.02, up from $1.78 a year ago.
  • Zoetis reported second quarter revenue of $2.5 billion, which was flat compared to the same period last year.
  • Net income for the quarter was $691 million, or $1.65 per diluted share.
  • U.S. revenue declined 7% due to softer demand in companion animal products and increased competition.

Results vs analyst consensus

Revenue

Reported

$2.47B

Consensus not captured before release

−0.2% YoY

Adjusted EPS

Reported · Adjusted Diluted EPS

$1.87

Consensus $1.85

Beat by $0.02

GAAP EPS: $1.65

Consensus: Yahoo Finance · Q2 2026 · EPS estimate at release
Revenue display rounded; difference uses exact result.

Next quarter outlook

$9.12B–$9.32B

Full Year 2026 revenue guidance

Next-quarter consensus not captured before release.

What to watch

  • Companion animal market demand is pressured by lower clinic visits and pet owner price sensitivity.
  • Key dermatology and pain products faced heightened competitive pressure and generic competition.
Read original report

Source: Zoetis Inc. press release · SEC Form 8-K exhibit 99.1

Figures as stated in the company’s release; consensus from the provider named above. Not financial advice.